Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. Dec 5, 2025; 16(4): 110642
Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.110642
Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.110642
Real-world effectiveness and safety of teduglutide in adult and pediatric patients with short bowel syndrome in Argentina
Héctor Solar Muñiz, María Inés Martínez, Carolina Rumbo, Department of Nutritional Support, Rehabilitation and Intestinal Transplant, Fundación Favaloro, Buenos Aires C1093, Argentina
Adriana Fernández, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata B1900, Buenos Aires, Argentina
Verónica Busoni, Gastroenterology and Hepatology Unit, Department of Pediatrics, Hospital Italiano de Buenos Aires, Buenos Aires C1181, Argentina
Silvia De Barrio, Department of Gastroenterology, Hospital Interzonal General de Agudos General José de San Martin, La Plata B1900, Buenos Aires, Argentina
Carola Saure, Department of Pediatric Nutrition, Hospital J. P. Garrahan, Buenos Aires C1245, Argentina
Martín Balacco, Department of Pediatric Intensive Care, Hospital de Niños Santísima Trinidad de Córdoba, Cordoba X5000, Argentina
Martín Gonzalo Buncuga, Department of Internal Medicine, Clínica Delta de Rosario, Rosario S2000, Santa Fe, Argentina
Corina Dlugoszweski, Department of Pediatric Nutrition, Hospital Materno Infantil de Salta, Salta A4400, Argentina
Alejandra Manzur, Department of Internal Medicine, Clínica de Cuyo, Mendoza M5500, Argentina
Lorena Rudi, Department of Pediatric Nutrition, Hospital Posadas, Buenos Aires B1684, Argentina
María Dolores Matoso, Department of Gastroenterology, Hospital Italiano de Buenos Aires, Buenos Aires C1181, Argentina
Sandra Cosentino, Department of Pediatric Nutrition, Clinica San Lucas, Neuquen Q8300, Argentina
Federico Ussher, Fernando Manzur, Julia Demarchi, Elisa Malaver, Laura Brion, Laura Ungar, Department of Medical Affairs, Takeda Argentina SA, Buenos Aires C1429, Argentina
Author contributions: Solar Muñiz H, Fernández A, Busoni V, Martínez MI, Rumbo C, De Barrio S, Saure C, Balacco M, Buncuga MG, Dlugoszweski C, Manzur A, Rudi L, Matoso MD, and Cosentino S enrolled patients, incorporated patient data into the electronic case report form and analyzed the data; Ussher F, Manzur F, Demarchi J, Malaver E, Brion L, and Ungar L analyzed the data and wrote the manuscript; Ungar L developed the protocol and managed the study; all authors have read and approved the final manuscript.
Supported by Takeda Argentina SA, No. TAK-633-4003.
Institutional review board statement: The study protocol (TAK-633-4003) was approved by an Independent Ethics Committee (Fundación de Estudios Farmacológicos y Medicamentos) on September 25, 2020.
Informed consent statement: All patients or their legal guardian were required to sign the applicable mandatory written informed consent.
Conflict-of-interest statement: Solar Muñiz H, Fernández A, Busoni V, Martínez MI, Rumbo C, De Barrio S, and Saure C received speaker and advisory board fees and travel support from Takeda Argentina SA; Buncuga MG serves as regional medical manager at NutriHome SA; Buncuga MG, Dlugoszweski C, Manzur A, Rudi L, Matoso MD, and Cosentino S have nothing to declare; Manzur F, Demarchi J, Malaver E, Brion L, and Ungar L are employees of Takeda Argentina SA and do not hold stocks; Ussher F was employee of Takeda Argentina SA at the time this study was conducted.
STROBE statement: The authors have read the STROBE Statement – checklist of items, and the manuscript was prepared and revised according to the STROBE Statement – checklist of items.
Data sharing statement: Participants have not consented to data sharing. No additional data are available.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Laura Ungar, MD, Department of Medical Affairs, Takeda Argentina SA, Avenida Del Libertador 7208, Buenos Aires C1429, Argentina. laura.ungar@takeda.com
Received: June 11, 2025
Revised: August 14, 2025
Accepted: November 17, 2025
Published online: December 5, 2025
Processing time: 177 Days and 12.9 Hours
Revised: August 14, 2025
Accepted: November 17, 2025
Published online: December 5, 2025
Processing time: 177 Days and 12.9 Hours
Core Tip
Core Tip: This multicenter real-world evidence study demonstrates the effectiveness and safety of teduglutide in adult and pediatric patients with short bowel syndrome-IF in the Latin American population. The results showed that teduglutide induced significant reductions in parenteral support (PS) in both adult and pediatric populations, consistent with pivotal studies, with a low incidence of mild to moderate adverse events. The findings highlight the importance of early identification of eligible patients for teduglutide (patients with reduced baseline PS volume dependence and/or favorable bowel anatomy), which may increase the likelihood of achieving PS independence. This approach could potentially reduce the morbidity associated with intestinal failure, ultimately improving long-term patient outcomes in Latin America.